Unicycive Therapeutics, Inc. (UNCY) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$4.78

From 52W high−43.93%

Volume1.07M

Market cap$133.71M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$4.78

From 52W high

−43.93%

Volume

1.07M

Market cap

$133.71M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.1x

P/E (TTM)

—

RSI (14)

39.2

MomentumView details →

1D Return

+0.63%

YTD Return

−16.90%

SummaryUpdated Jun 1, 2026

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) is a clinical-stage biotechnology company founded in 2016 and headquartered in Los Altos, California. The company went public in July 2021 and focuses exclusively on developing innovative therapeutic treatments for kidney diseases, an area of significant unmet medical need. As a pre-revenue biotech company, Unicycive is currently advancing its pipeline of kidney-focused drug candidates through various stages of clinical development, with its lead programs targeting chronic kidney disease complications and acute kidney injury.

Ask drillr about Unicycive Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−2.1x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

2.5x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−66.12%

ROA (TTM)

−48.90%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+42.98%

FCF YoY

+16.10%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+70.44%

EBITDA YoY

−83.74%

MomentumView details →

1D Return

+0.63%

YTD Return

−16.90%

1Y Return

+21.09%

RSI (14)

39.2

vs 50D SMA

−7.76%

vs 200D SMA

−24.51%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

3.81x

Quick Ratio

3.81x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.06

EPS Surprise

87.26%

Beats (12Q)

6/12

Next Q EPS Est

−$0.35

Avg Surprise (4Q)

5.09%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−35.22M

Op. CF (TTM)

−27.84M

Next earningsNov 11, 2026 →

Latest newsMore news →

A securities class action lawsuit was filed against Unicycive Therapeutics on behalf of investors who purchased securities between December 29, 2025 and June 29, 2026, alleging false and misleading statements about its third-party manufacturing vendor's compliance with good manufacturing practices.10d ago

Similar companies

TuHURA Biosciences, Inc.HURA ADC Therapeutics S.A.ADCT Biomea Fusion, Inc.BMEA Insight Molecular Diagnostics Inc.IMDX Neumora Therapeutics, Inc. Common StockNMRA Caribou Biosciences, Inc.CRBU Find similar companies →

Latest newsMore news →

Kaplan Fox & Kilsheimer LLP announced that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. on behalf of investors who acquired Unicycive securities between December 29, 2025 and June 29, 2026.9d ago A securities class action lawsuit was filed against Unicycive Therapeutics on behalf of investors who purchased securities between December 29, 2025 and June 29, 2026, alleging false and misleading statements about its third-party manufacturing vendor's compliance with good manufacturing practices.10d ago Unicycive Therapeutics, Inc. has been sued for securities law violations, and the DJS Law Group is inviting affected investors to discuss their rights.13d ago